Dark Forest Capital Management LP Sells 659 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Dark Forest Capital Management LP has recently sold 659 shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for an undisclosed amount. This represents a significant reduction in their holdings, as they previously owned approximately 1.2 million shares of the company.

Regeneron is a biotechnology company that develops and commercializes medicines for various diseases, including cancer, rheumatoid arthritis, and asthma. The company's flagship product is Eylea, an eye treatment for wet age-related macular degeneration (AMD), which was approved by the US Food and Drug Administration (FDA) in 2015.

Dark Forest Capital Management LP is a private equity firm that specializes in investing in healthcare companies. They have a long history of success in the industry, with investments in companies such as Genzyme Corporation, which was acquired by Sanofi for $31 billion in 2011.

It's worth noting that the reason behind this sale is not disclosed and it could be due to various reasons such as portfolio rebalancing or changes in investment strategy. Additionally, it's important to note that this information is based on publicly available data and should not be considered as financial advice.